Skip to main content
. 2014 Aug 14;64(1):193–199. doi: 10.2337/db14-0436

Table 2.

GPA test parameters

ABCA1
Low HDL-C
Homozygous Heterozygous Control subjects Case subjects Control subjects
n = 3 n = 8 n = 8 n = 9 n = 9
AIRarg (μU/mL) 62 ± 32a 33 ± 8 28 ± 7 58 ± 10* 27 ± 6
AIRpot (µU/mL) 350 ± 228a 195 ± 33* 122 ± 20 278 ± 45 134 ± 14
AIRmax (µU/mL) 426 ± 153* 219 ± 30* 173 ± 34 304 ± 66 143 ± 20
ACRarg (ng/mL) 3.47 ± 0.86* 2.03 ± 0.36* 1.43 ± 0.26 3.07 ± 0.29* 1.64 ± 0.25
ACRpot (ng/mL) 14.17 ± 6.24a 8.31 ± 1.70* 6.30 ± 0.97 9.70 ± 1.06 5.24 ± 0.52
ACRmax (ng/mL) 14.08 ± 6.01* 8.39 ± 1.16* 5.77 ± 0.55 10.45 ± 1.66* 5.60 ± 0.65
M (mg/kg/min) 9.8 ± 0.1 9.6 ± 0.5 9.4 ± 0.7 8.7 ± 0.4 10.3 ± 1.0
I (µU/mL) 52 ± 25 45 ± 11 28 ± 4 50 ± 10 34 ± 6
M/I (mg/kg per min/µU/mL) 0.30 ± 0.12 0.29 ± 0.05 0.36 ± 0.03 0.22 ± 0.03 0.37 ± 0.06
DI (mg/kg/min) 11.0 ± 1.8 9.0 ± 2.6 9.7 ± 2.3 11.0 ± 1.5 10.4 ± 3.6

Data are means ± SE.

ACRarg, acute C-peptide response to arginine under fasting conditions; ACRmax, acute C-peptide response to arginine under ∼340 mg/dL glucose clamp conditions; ACRpot, acute C-peptide response to arginine under ∼230 mg/dL glucose clamp conditions.

aP ≤ 0.1 case subjects vs. control subjects.

*P < 0.05 case subjects vs. control subjects.

P < 0.01 case subjects vs. control subjects.